Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

被引：0
|
作者：
Dent, S. [1 ]
Alder, L. [1 ]
Broadwater, G. [1 ]
Hyslop, T. [1 ]
Oeffinger, K. [1 ]
Khouri, M. [1 ]
Balu, S. [2 ]
Kimmick, G. [1 ]
机构：
[1] Duke Canc Inst, Cardiooncol, Durham, NC USA
[2] Novartis Pharmaceut, HEOR, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 50 条
  • [21] The emerging role of CDK4/6i in HER2-positive breast cancer
    O'Sullivan, Ciara C.
    Suman, Vera J.
    Goetz, Matthew P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [22] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
    Pu, Dongqing
    Xu, Debo
    Wu, Yue
    Chen, Hanhan
    Shi, Guangxi
    Feng, Dandan
    Zhang, Mengdi
    Liu, Zhiyong
    Li, Jingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
  • [23] CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort
    Javaid, Anadil
    Lok, Sheau Wen
    Wong, Vanessa
    Baron-Hay, Sally
    Boyle, Fran
    Collins, Ian
    Cuff, Katharine
    de Boer, Richard
    Gately, Lucy
    Georgiou, Chloe
    Greenberg, Sally
    Karki, Bhaskar
    Nottage, Michelle
    Rainey, Natalie
    Torres, Javier
    Yeo, Belinda
    Devitt, Bianca
    Gibbs, Peter
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 129 - 130
  • [24] Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2–advanced breast cancer
    Qi Zhao
    Mingxia Jiang
    Jiaxuan Liu
    Mengqi Zhang
    Maiyue He
    Shihan Zhou
    Jiani Wang
    Hongnan Mo
    Bo Lan
    Peng Yuan
    Pin Zhang
    Fei Ma
    Qiao Li
    Binghe Xu
    Cancer Biology & Medicine, 2024, 21 (10) : 934 - 950
  • [25] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [26] Therapy of HR+/HER2-advanced Breast Cancer CDK4/6 Inhibitors: Studies, Everyday Healthcare and Guidelines
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [27] Study Supports Delay of CDK4/6 Inhibitors Until Second-Line Treatment in Advanced HR+/HER2- Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 352 - 353
  • [28] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [29] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
  • [30] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
12345